In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI

Trial ID or NCT#

NCT03179449

Status

not recruiting iconNOT RECRUITING

Purpose

This pilot early phase I trial studies how well ferumoxytol-enhanced magnetic resonance imaging (MRI) correlates with inflammatory (macrophage) responses in pediatric patients with malignant brain tumors. If there is good correlation, ferumoxytol-enhanced MRI can serve as a noninvasive imaging biomarker of inflammation.

Official Title

MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI (Pediatric Brain Tumor Protocol)

Eligibility Criteria

Ages Eligible for Study: Older than 2 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Any patient with suspected malignant brain tumor on diagnostic MR imaging who will undergo a resection
Exclusion Criteria:
  1. - Informed consent cannot be obtained either from the patient or legal representative - Severe coexisting or terminal systemic disease that may interfere with the conduct of the study - Contraindication to MRI (metal implants) - Hemosiderosis/hemochromatosis - Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or parenteral iron, or any other etiology - Known hypersensitivity to ferumoxytol or any of its components - Pregnant patients
View All Criteria
Show Less

Investigator(s)

Michael Iv
Michael Iv
Radiologist
Clinical Professor, Radiology
Michael S. B. Edwards, MD

Contact us to find out if this trial is right for you.

Contact

Paymon Rezaii
650-743-8336

View on ClinicalTrials.gov